– $65M Series B Raise Led by New Investors venBio Partners and Cormorant Asset Management, with Participation by Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, and All Existing Series A Investors –
– Shawn M. Leland, Founder of Elevation Oncology, Named Chief Executive Officer; Steve Elms, Managing Partner of Aisling Capital, to Remain Chair of Elevation Oncology Board of Directors –
NEW YORK, Nov. 18, 2020 /PRNewswire/ —Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series B financing of $65 million led by new investors, venBio Partners and Cormorant Asset Management, and the promotion of Shawn M. Leland, PharmD, RPh, the Company’s founder, to Chief Executive Officer. Additional participants in the financing include Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, and Vivo Capital, as well as all of Elevation Oncology’s existing investors: Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.
